GE Healthcare Acquires Puridify

GE Healthcare has acquired Puridify, a bioprocessing start-up that is developing a nanofiber-based platform purification technology called FibroSelect for biopharmaceutical production.

Puridify has collaborated with several major biopharmaceutical manufacturers in the development of FibroSelect, and their platform is expected to bring productivity improvements in the process development (PD) phase and small-scale manufacturing for a wide variety of biopharmaceutical applications.

“Puridify has spent the last three years developing the industrial FibroSelect technology in close collaboration with leading biomanufacturers with promising results. We are excited to take this next step as part of GE Healthcare, with the full support and experience associated with one of the industry leaders in this field.” said Oliver Hardick, chief executive officer of Puridify.

The company’s 17 employees will join GE Healthcare Life Sciences’ BioProcess business, but will remain at their current location in Stevenage, UK, which will serve as a small research hub for BioProcess.